Buying Modis will add MT1621 to Zogenix’s pipeline, an investigational drug for thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial DNA depletion disorder that affects children and ...

The data show that in individuals with TK2d who were aged 12 years or less when their symptoms first appeared, treatment with pyrimidine nucleoside and/or nucleotide therapy significantly ...

Thymidine Kinase 2 deficiency (TK2d) is a rare, life-threatening genetic disorder that primarily affects mitochondrial function due to mutations in the TK2 gene. This condition leads to a ...

6,7,8,9,10 “There are no approved therapies or international clinical guidelines for the management of TK2d, therefore we are very excited to share this data with the medical community at MDA," said ...

1,2,3 Additional patient experience data emphasize the profound physical challenges and severe psychological strain that come with living with TK2d, and the heavy emotional and physical burden ...

6,7,8,9,10 "There are no approved therapies or international clinical guidelines for the management of TK2d, therefore we are very excited to share this data with the medical community at MDA ...